BIN XIONG

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Trastuzumab has been demonstrated to be an effective treatment in patients with human epidermal growth factor receptor-2 (HER-2) positive breast cancer (BC); however, inconsistent results with regards to the long-term survival benefits, safety and optimal administration timing of trastuzumab exist. The present meta‑analysis investigated these(More)
  • 1